Immune proteins in the blood of people with brain tumors
Original title: TLR2 and TLR9 in Brain Cancer Patients in Relation to EBV Status.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Blood and tissue from patients were studied, but no treatment was tested.
The short version
People with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary had higher levels of two immune proteins in their blood.
What was studied. Researchers measured two immune proteins, called TLR2 and TLR9, in the blood of people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They also looked for signs of the Epstein-Barr virus in the blood and in tumor tissue.
What they found. TLR2 and TLR9 levels were higher in people with glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary than in the comparison groups. People who tested positive for the virus had lower TLR9 levels. TLR9 levels were also linked to signs of the virus inside the tumor tissue.
What this means, and what it doesn't
What it could mean: This is early science about how the immune system behaves in brain tumors. It does not change the care anyone gets today. Doctors do not use these blood proteins to guide brain tumor treatment.
What it doesn't mean: This is not a treatment, and it is not a cure. It is early research on blood and tissue samples, far from everyday care. It does not show that the virus causes brain tumors. The researchers say much more study is needed.
Source: PubMed, September 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.